GlobeNewswire Inc.··Not SpecifiedImmuron Lifts H1 Revenue on U.S. Growth, Pursues Partnership Strategy
Immuron lifted H1 revenue 5% to AUD$4.2M with strong U.S. growth of 17%. The company secured AUD$7.3M funding and is pursuing partnerships to advance its clinical pipeline.
IMRNFDA approvalclinical trials